PPARG and non-small cell lung carcinoma: Increasing evidence has indicated that PPAR-γ agonists may serve as master modulators for overcoming classic obstacles associated with targeted NSCLC therapies, including resistance to therapy and tumor genetic heterogeneity (144–146).